Komii)EPISODE 05 Ozempic: The Miracle Drug That Made Denmark Bigger Than LVMH

The Anatomy of a Pen

This is Ozempic—an injection pen, plastic, about the length of a marker, with a dial on one end. In a German pharmacy, on the statutory insurance system, a pen of semaglutide has sold for around fifty-nine euros, whereas in the United States, the list price for the same molecule, made by the same company, has run close to nine hundred and seventy dollars a month.

Now, before you jump to the obvious, this is not because Americans get a better version, not a different formulation, and not a different factory. It is the exact same drug. And this one molecule did something no product has done in modern European history: it made a Danish company worth more than LVMH, and then worth more than the entire economy of Denmark.

So here is the question that does not resolve: if a company can sell this profitably in Germany for fifty-nine euros, what exactly is the other nine hundred dollars for? I went through Novo Nordisk's earnings, the Danish national accounts, the pricing data, and the company's own announcement about what it plans to charge next year. And the answer is not greed, because greed is the lazy answer that explains nothing. The answer is a machine, and the same machine that built this company is now taking it apart.

The Stakes

Start with what it did to a country: Novo Nordisk's market capitalisation passed five hundred and seventy billion dollars, which is larger than the entire annual economic output of Denmark. In twenty twenty three the company accounted for roughly fifteen percent of Denmark's tax intake and around twenty percent of the country's new jobs. Danish GDP grew one point seven percent in the first half of that year, but strip out the pharmaceutical sector, and it would have shrunk by zero point three percent.

Read that again: without this one company, Denmark's economy was going backwards.

Quick thing before we open the machinery: most people who watch these all the way through still are not subscribed. If you like understanding how the money actually moves, hit subscribe.

The Mechanism

In nineteen twenty, the English economist Arthur Cecil Pigou set out what we now call price discrimination. The idea is simple: if you can separate your customers into groups and stop them trading with each other, you can charge each group the maximum it will bear for the same product and cost to make, but at a completely different price.

Now apply it to medicine. Germany negotiates as one buyer for eighty-three million people through its statutory insurance system, Denmark negotiates as one buyer, and Britain negotiates as one buyer. When there is a single purchaser, that purchaser can say no, and a company facing a buyer who can walk away discovers that fifty-nine euros is, in fact, a profitable price.

The United States does not do this. It buys through thousands of separate insurers, employers, and plans, with a layer of middlemen called pharmacy benefit managers sitting between the manufacturer and the patient, negotiating confidential rebates almost nobody outside the industry can see. So the list price is not really a price; it is an opening bid in a negotiation the patient is not present for. Hold that, because it explains not just why Americans pay ten times more, but why the company that profited most from it is now in serious trouble.

The Rise

Novo Nordisk did not appear from nowhere. In nineteen twenty-three, a Danish couple, August and Marie Krogh, brought the rights to manufacture insulin back to Denmark from Canada, sparked by the fact that Marie Krogh had diabetes and August Krogh had a Nobel Prize. For a century afterwards, the company did one thing obsessively: peptides and injectable metabolic medicine.

That patience is the whole story. Semaglutide is a synthetic version of GLP one, a hormone your body already produces, which was originally developed for diabetes before the weight loss was discovered as a side effect. In September twenty twenty three, Novo Nordisk overtook LVMH to become the most valuable listed company in Europe, meaning a Danish insulin maker was suddenly worth more than Louis Vuitton, Dior, Moët, and the entire luxury empire behind them.

And keep hold of this, because it matters later: when a branded drug goes into official shortage in the United States, compounding pharmacies are permitted to produce their own versions of it.

The Crack

The competitor was never really the compounders, however; it was Indiana. Eli Lilly had been working the same biology from a different angle with a molecule called tirzepatide. In twenty twenty-five, combined sales of Mounjaro and Zepbound reached roughly thirty-six billion dollars, overtaking Ozempic and Wegovy.

Novo's position collapsed with remarkable speed. Guidance was cut, around four hundred and eighty billion dollars of market value came off the company, and in February twenty twenty six the stock dropped about fifteen percent in a single session as part of a fall of roughly twenty-one percent over a month, leading to the replacement of the chief executive. The new chief executive, Mike Doustdar, told CNBC something refreshingly blunt for a man in his position: people should expect that it goes down before it comes back up. And this is where it gets strange, because the thing that hurt Novo most was not the competitor.

The Self-Inflicted Wound

Go back to that pricing machine. A high American list price is enormously profitable while you are the only option, but it is also a standing invitation that tells every competitor, compounding pharmacy, and generic manufacturer on earth exactly how much room there is underneath you.

So the room got filled. Compounded semaglutide spread across the United States during the shortage, and by April twenty twenty six, generics were flooding India. When Americans could see that Germans pay fifty-nine euros, the pricing stopped being an industry arrangement and became a national argument. Consequently, Novo Nordisk announced that from January first, twenty twenty seven, it will cut the United States list price of Ozempic to six hundred and seventy-five dollars—a reduction of around thirty-five percent.

Think about what that means: nothing changed about the cost of manufacture, there is no new science and no new factory, but the company simply decided a lower number was now better for business, which tells you the old number was never about cost. Even still, six hundred and seventy-five dollars remains more than ten times the German price.

The Exception

So who got this right? Denmark did. A country of under six million people whose largest company and biggest taxpayer is Novo Nordisk had, on paper, no leverage at all.

Except that Denmark buys as one. Danish health authorities negotiate for the whole country, and they were willing to decline coverage. Health policy journalists documented that this pressure produced lower prices at home from a company the country had every incentive to protect. That is the lesson, and it has nothing to do with pharmaceuticals: a price is not a fact about a product, but a fact about a relationship. A single buyer who can genuinely walk away pays one price, whereas ten thousand fragmented buyers who cannot coordinate pay another, and the molecule does not know the difference.

If you know somebody paying for one of these out of pocket or arguing with an insurer, send them this. Send it to three people, because most patients have never been shown what the same pen costs across a border.

The Counter Case

Now consider the other side properly, because it is stronger than the internet suggests: Novo Nordisk invented this, driven not by a marketing department, but by scientists working on peptide chemistry for decades. That is exactly what we want from a pharmaceutical industry, and it is rarer than it should be, with the failed programmes being paid for by the ones that work. Furthermore, the drugs are not a cosmetic indulgence, as the clinical results in diabetes and cardiovascular risk are substantial.

One thing I want to say plainly, because it matters more than anything else here: if you take any of these medicines, nothing in this video is a reason to stop or to change how you take them on your own, as that decision belongs with your doctor. That is not a disclaimer bolted on the end; it is the actual point, since the entire problem in this story is people making decisions about medicine without being shown the full information.

The Final Verdict

In December twenty twenty five, an oral version of Wegovy was approved, sales beat forecasts, and the stock recovered ground. Meanwhile, the patents weaken, and generics are already being made at a fraction of the price, meaning either competition does what regulation would not, or the branded product simply moves to whichever markets still cannot negotiate.

Back to the pen: it is the same object in every country with the same plastic, the same dial, and the same molecule. What changes when it crosses a border is not the medicine, but who is standing on the other side of the table and whether that person can say no.

So tell me, if a company can profitably sell a medicine for fifty-nine euros in one country, should it be allowed to charge nine hundred in another? Yes or no, leave it in the comments, because I read them.

And most of you are not subscribed, so if this was worth your time, that is the whole ask—just one click.

Because next time we are going after a murder on the front steps of a Miami mansion, a green dress that changed how the internet works, and eight hundred million dollars that vanished twenty years after the funeral. See you there.